drugset
drugset / Trial / NCT04199559

Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer

NCT04199559 ↗

Phase 1/2 Unknown 30 enrolled Henan Cancer Hospital Cttq · collab
NaSingle-groupOpen-labelTreatment

Summary

Study Arms: Patients receive autologous dendritic cells pulsed with antigen peptides ID on days 15, 29, 43,57,71,99,127and 155, and nivolumab IV over 60 minutes on days 15, 29, 43,57,71,85 99 and 113.

Timeline

Start
2019-12-01
Primary completion
2021-01-01
Completion
2022-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous dendritic cells pulsed with antigen Cell therapy 1e+07 cells Intrathecal

Indications

non-small cell lung carcinoma